ChromaDex (CDXC) News Today $5.94 +0.29 (+5.13%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 6.7%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, a growth of 6.7% from the December 15th total of 1,940,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 4.3% of the shares of the company are short sold.January 19 at 5:13 PM | marketbeat.comChromaDex (NASDAQ:CDXC) Downgraded by StockNews.com to BuyJanuary 15, 2025 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Rating Lowered to "Buy" at StockNews.comStockNews.com downgraded ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Wednesday.January 15, 2025 | marketbeat.comChromaDex (NASDAQ:CDXC) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedChromaDex (NASDAQ:CDXC) Stock Passes Above 200-Day Moving Average - Should You Sell?January 14, 2025 | marketbeat.comChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025January 6, 2025 | businesswire.comChromaDex (NASDAQ:CDXC) Stock Rating Lowered by StockNews.comStockNews.com downgraded ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Friday.January 3, 2025 | marketbeat.comChromaDex (NASDAQ:CDXC) Shares Cross Above 200-Day Moving Average - Here's What HappenedChromaDex (NASDAQ:CDXC) Share Price Crosses Above 200-Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comStockNews.com Upgrades ChromaDex (NASDAQ:CDXC) to "Strong-Buy"StockNews.com upgraded shares of ChromaDex from a "buy" rating to a "strong-buy" rating in a report on Wednesday.December 25, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Lowered to Buy Rating by StockNews.comStockNews.com cut ChromaDex from a "strong-buy" rating to a "buy" rating in a research note on Tuesday.December 17, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Director Frank L. Jaksch, Jr. Sells 37,161 SharesDecember 14, 2024 | insidertrades.comFrank L. Jaksch, Jr. Sells 37,161 Shares of ChromaDex Co. (NASDAQ:CDXC) StockChromaDex Co. (NASDAQ:CDXC - Get Free Report) Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company's stock, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.December 13, 2024 | marketbeat.comEven though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 yearDecember 10, 2024 | finance.yahoo.comChromaDex 8-K ‘may have been misconstrued’ by market, says LadenburgDecember 6, 2024 | markets.businessinsider.comChromaDex (NASDAQ:CDXC) Shares Gap Up - Should You Buy?ChromaDex (NASDAQ:CDXC) Shares Gap Up - Still a Buy?December 6, 2024 | marketbeat.comChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryDecember 3, 2024 | businesswire.comInsider Buying: ChromaDex Co. (NASDAQ:CDXC) CFO Purchases 2,907 Shares of StockNovember 26, 2024 | insidertrades.comChromaDex Co. (NASDAQ:CDXC) CFO Buys $21,395.52 in StockChromaDex Co. (NASDAQ:CDXC - Get Free Report) CFO Ozan Pamir bought 2,907 shares of ChromaDex stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average price of $7.36 per share, with a total value of $21,395.52. Following the completion of the transaction, the chief financial officer now owns 2,907 shares of the company's stock, valued at $21,395.52. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.November 25, 2024 | marketbeat.comChromaDex updates equity offering program, adds Roth Capital PartnersNovember 23, 2024 | investing.comChromaDex (NASDAQ:CDXC) Trading Down 5.5% - Time to Sell?ChromaDex (NASDAQ:CDXC) Stock Price Down 5.5% - Here's What HappenedNovember 22, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Short Interest UpdateChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 2,600,000 shares, a drop of 12.2% from the October 15th total of 2,960,000 shares. Based on an average daily volume of 993,800 shares, the days-to-cover ratio is currently 2.6 days. Currently, 5.4% of the shares of the stock are sold short.November 16, 2024 | marketbeat.comChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity SupplementNovember 14, 2024 | businesswire.comChromaDex (NASDAQ:CDXC) Sets New 12-Month High - Here's WhyChromaDex (NASDAQ:CDXC) Sets New 1-Year High - Here's What HappenedNovember 12, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Cut to "Buy" at StockNews.comStockNews.com downgraded shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Friday.November 8, 2024 | marketbeat.comShareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High QualityNovember 8, 2024 | uk.finance.yahoo.comWhat is Roth Capital's Estimate for ChromaDex Q2 Earnings?ChromaDex Co. (NASDAQ:CDXC - Free Report) - Stock analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of ChromaDex in a report released on Tuesday, November 5th. Roth Capital analyst S. Mcgowan expects that the company will post earnings per share of $0.01November 8, 2024 | marketbeat.comChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics NationwideNovember 7, 2024 | businesswire.comWhat is Roth Capital's Forecast for ChromaDex Q4 Earnings?ChromaDex Co. (NASDAQ:CDXC - Free Report) - Stock analysts at Roth Capital lowered their Q4 2024 EPS estimates for shares of ChromaDex in a report issued on Tuesday, November 5th. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings per share of $0.00 for the quarter,November 7, 2024 | marketbeat.comChromaDex price target raised to $8 from $6 at Roth MKMNovember 6, 2024 | markets.businessinsider.comChromaDex FY2025 EPS Estimate Increased by HC WainwrightChromaDex Co. (NASDAQ:CDXC - Free Report) - Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of ChromaDex in a research report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per sharNovember 6, 2024 | marketbeat.comAnalysts Set Expectations for ChromaDex FY2024 EarningsChromaDex Co. (NASDAQ:CDXC - Free Report) - Equities researchers at HC Wainwright upped their FY2024 earnings estimates for ChromaDex in a report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.06 for the year, uNovember 5, 2024 | marketbeat.comChromaDex’s Robust Q3 Performance and Strategic Initiatives Drive ‘Buy’ Rating with Raised Price TargetNovember 4, 2024 | markets.businessinsider.comChromaDex price target raised to $8 from $6 at H.C. WainwrightNovember 4, 2024 | markets.businessinsider.comHC Wainwright Issues Positive Forecast for ChromaDex (NASDAQ:CDXC) Stock PriceHC Wainwright raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Monday.November 4, 2024 | marketbeat.comBSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC)BSW Wealth Partners bought a new stake in ChromaDex Co. (NASDAQ:CDXC - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 88,847 shares of the company's stock, valued at approximately $324,000. BSW Wealth PaNovember 4, 2024 | marketbeat.comEquities Analysts Issue Forecasts for ChromaDex Q2 EarningsChromaDex Co. (NASDAQ:CDXC - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2025 earnings estimates for shares of ChromaDex in a report released on Friday, November 1st. Roth Capital analyst S. Mcgowan now anticipates that the company will post earnings per share of $0November 4, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Issues Quarterly Earnings ResultsChromaDex (NASDAQ:CDXC - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 5.06%. The business had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period in the previous year, the firm earned ($0.01) EPS.November 3, 2024 | marketbeat.comChromaDex Third Quarter 2024 Earnings: Beats ExpectationsNovember 2, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q3 2024 Earnings Report Preview: What To ExpectNovember 1, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...November 1, 2024 | finance.yahoo.comChromaDex Corporation 2024 Q3 - Results - Earnings Call PresentationNovember 1, 2024 | seekingalpha.comChromaDex Shares Climb on Forecast for 15% Revenue GrowthNovember 1, 2024 | marketwatch.comChromaDex Corporation Reports Third Quarter 2024 Financial ResultsNovember 1, 2024 | finance.yahoo.comChromaDex Reports Strong Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comChromadex Reports Strong Q3 2024 with 31% Sales IncreaseNovember 1, 2024 | markets.businessinsider.comInsights into ChromaDex's Upcoming EarningsOctober 31, 2024 | benzinga.comChromaDex Co. (NASDAQ:CDXC) Sees Significant Drop in Short InterestChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,960,000 shares, a drop of 7.5% from the September 30th total of 3,200,000 shares. Based on an average daily volume of 264,700 shares, the short-interest ratio is presently 11.2 days. Currently, 6.2% of the shares of the company are short sold.October 30, 2024 | marketbeat.comChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024October 28, 2024 | businesswire.comChromaDex (CDXC) to Release Earnings on ThursdayChromaDex (NASDAQ:CDXC) will be releasing earnings after the market closes on Thursday, October 31, Zacks reports.October 25, 2024 | marketbeat.comChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024October 24, 2024 | businesswire.comChromaDex to Participate in the 17th Annual LD Micro Main EventOctober 23, 2024 | businesswire.com Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXC Media Mentions By Week CDXC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDXC News Sentiment▼0.270.44▲Average Medical News Sentiment CDXC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDXC Articles This Week▼42▲CDXC Articles Average Week Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News Today TARS News Today AKRO News Today BLTE News Today IRON News Today AMPH News Today WVE News Today APGE News Today INDV News Today GLPG News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDXC) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDXC Stock Alerts